Association of baseline laboratory and clinical variables with eGFR decline to normal range using age as the timescale
| Variables . | CKD-EPI–2009 . | CKD-EPI–2021 . | ||
|---|---|---|---|---|
| HR (95% CI) . | P value . | HR (95% CI) . | P value . | |
| Male sex | 2.10 (1.32-3.35) | .002 | 2.71 (1.74-4.24) | <.0001 |
| White blood cell count | 1.002 (0.94-1.07) | .96 | 1.0 (0.94-1.05) | .85 |
| Hemoglobin | 1.15 (0.94-1.39) | .18 | 1.07 (0.88-1.29) | .52 |
| Hematocrit | 1.01 (0.95-1.08) | .72 | 1.0 (0.93-1.07) | .92 |
| Platelet count | 1.0 (1.0-1.001) | .31 | 1.0 (1.0-1.001) | .43 |
| Reticulocyte count | 1.0 (1.0-1.001) | .31 | 1.0 (1.0-1.001) | .20 |
| Hemoglobin F | 1.002 (0.95-1.05) | .94 | 0.98 (0.93-1.03) | .35 |
| Blood urea nitrogen | 1.03 (0.90-1.17) | .71 | 1.06 (0.93-1.20) | .42 |
| eGFR | 0.97 (0.94-0.99) | .03 | 0.94 (0.92-0.95) | <.0001 |
| Ferritin (per 100 units) | 1.02 (1.002-1.05) | .04 | 1.02 (1.0-1.05) | .06 |
| Total bilirubin | 0.95 (0.86-1.06) | .38 | 0.97 (0.88-1.07) | .55 |
| Direct bilirubin | 1.91 (0.47-7.80) | .37 | 2.05 (0.50-8.33) | .32 |
| Indirect bilirubin | 1.02 (0.82-1.27) | .86 | 1.02 (0.82-1.26) | .89 |
| Hemoglobinuria | 0.31 (0.10-0.98) | .05 | 0.44 (0.16-1.23) | .12 |
| Proteinuria | 0.33 (0.11-0.98) | .05 | 0.43 (0.17-1.08) | .07 |
| Systolic blood pressure | 1.02 (1.003-1.03) | .02 | 1.01 (1.0-1.03) | .054 |
| Diastolic blood pressure | 1.01 (1.0-1.03) | .14 | 1.01 (0.99-1.03) | .39 |
| Weight | 1.01 (0.99-1.03) | .37 | 1.01 (0.99-1.03) | .34 |
| Height | 0.99 (0.94-1.03) | .55 | 0.99 (0.95-1.03) | .63 |
| Body mass index | 0.90 (0.63-1.29) | .57 | 0.93 (0.62-1.39) | .72 |
| History of diabetes | 6.0 (0.78-45.99) | .09 | 6.50 (0.85-49.93) | .07 |
| History of stroke | 0.84 (0.45-1.57) | .59 | 0.85 (0.47-1.54) | .58 |
| History of acute chest syndrome | 0.68 (0.39-1.17) | .17 | 1.03 (0.60-1.75) | .92 |
| History of avascular necrosis | 0.67 (0.34-1.30) | .24 | 0.61 (0.31-1.19) | .15 |
| History of leg ulcers | 1.78 (0.72-4.42) | .21 | 1.91 (0.67-5.48) | .23 |
| ACE-I/ARB therapy | 1.15 (0.15-8.86) | .89 | 1.33 (0.17-10.21) | .78 |
| Hydroxyurea therapy | 1.44 (0.91-2.29) | .12 | 1.27 (0.81-2.01) | .30 |
| Chronic RBC transfusion | 0.71 (0.28-1.82) | .48 | 1.65 (0.85-3.21) | .14 |
| Variables . | CKD-EPI–2009 . | CKD-EPI–2021 . | ||
|---|---|---|---|---|
| HR (95% CI) . | P value . | HR (95% CI) . | P value . | |
| Male sex | 2.10 (1.32-3.35) | .002 | 2.71 (1.74-4.24) | <.0001 |
| White blood cell count | 1.002 (0.94-1.07) | .96 | 1.0 (0.94-1.05) | .85 |
| Hemoglobin | 1.15 (0.94-1.39) | .18 | 1.07 (0.88-1.29) | .52 |
| Hematocrit | 1.01 (0.95-1.08) | .72 | 1.0 (0.93-1.07) | .92 |
| Platelet count | 1.0 (1.0-1.001) | .31 | 1.0 (1.0-1.001) | .43 |
| Reticulocyte count | 1.0 (1.0-1.001) | .31 | 1.0 (1.0-1.001) | .20 |
| Hemoglobin F | 1.002 (0.95-1.05) | .94 | 0.98 (0.93-1.03) | .35 |
| Blood urea nitrogen | 1.03 (0.90-1.17) | .71 | 1.06 (0.93-1.20) | .42 |
| eGFR | 0.97 (0.94-0.99) | .03 | 0.94 (0.92-0.95) | <.0001 |
| Ferritin (per 100 units) | 1.02 (1.002-1.05) | .04 | 1.02 (1.0-1.05) | .06 |
| Total bilirubin | 0.95 (0.86-1.06) | .38 | 0.97 (0.88-1.07) | .55 |
| Direct bilirubin | 1.91 (0.47-7.80) | .37 | 2.05 (0.50-8.33) | .32 |
| Indirect bilirubin | 1.02 (0.82-1.27) | .86 | 1.02 (0.82-1.26) | .89 |
| Hemoglobinuria | 0.31 (0.10-0.98) | .05 | 0.44 (0.16-1.23) | .12 |
| Proteinuria | 0.33 (0.11-0.98) | .05 | 0.43 (0.17-1.08) | .07 |
| Systolic blood pressure | 1.02 (1.003-1.03) | .02 | 1.01 (1.0-1.03) | .054 |
| Diastolic blood pressure | 1.01 (1.0-1.03) | .14 | 1.01 (0.99-1.03) | .39 |
| Weight | 1.01 (0.99-1.03) | .37 | 1.01 (0.99-1.03) | .34 |
| Height | 0.99 (0.94-1.03) | .55 | 0.99 (0.95-1.03) | .63 |
| Body mass index | 0.90 (0.63-1.29) | .57 | 0.93 (0.62-1.39) | .72 |
| History of diabetes | 6.0 (0.78-45.99) | .09 | 6.50 (0.85-49.93) | .07 |
| History of stroke | 0.84 (0.45-1.57) | .59 | 0.85 (0.47-1.54) | .58 |
| History of acute chest syndrome | 0.68 (0.39-1.17) | .17 | 1.03 (0.60-1.75) | .92 |
| History of avascular necrosis | 0.67 (0.34-1.30) | .24 | 0.61 (0.31-1.19) | .15 |
| History of leg ulcers | 1.78 (0.72-4.42) | .21 | 1.91 (0.67-5.48) | .23 |
| ACE-I/ARB therapy | 1.15 (0.15-8.86) | .89 | 1.33 (0.17-10.21) | .78 |
| Hydroxyurea therapy | 1.44 (0.91-2.29) | .12 | 1.27 (0.81-2.01) | .30 |
| Chronic RBC transfusion | 0.71 (0.28-1.82) | .48 | 1.65 (0.85-3.21) | .14 |
All variables (except sex) were adjusted for sex and cohort effect. Sex was adjusted for the cohort effect.
ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CKD-EPI-2009, Chronic Kidney Disease Epidemiology Collaboration formula for estimated glomerular filtration rate (omitting adjustment for the Black race), utilizing serum creatinine; CKD-EPI-2021, Chronic Kidney Disease Epidemiology Collaboration formula for estimated glomerular filtration rate, utilizing serum creatinine; RBC, red blood cell.